IdbyDNA, of San Francisco, a precision medicine company focused on metagenomic approaches for infectious disease identification, raised $9 million in series A financing. Artis Ventures led the round, with additional investments from Arup Laboratories and other private investors. The funds will be used to further develop the company's Taxonomer-based DNA search technologies and to launch metagenomics-based clinical tests for infectious diseases.
Insulet Corp., of Billerica, Mass., priced a private placement of $300 million principal amount of convertible senior notes due 2021. Due to investor demand, the offering size was increased from the previously reported $250 million principal amount. The notes will bear interest at an annual rate of 1.25 percent and will mature on Sept. 15, 2021, unless earlier converted, purchased or redeemed. Insulet also granted the initial purchasers of the notes an option to purchase up to an additional $45 million principal amount of notes.
Memed Ltd., of Tirat Carmel, India, said the European Commission awarded €2.3 million to support Autopilot-Dx, an international consortium with members from the medical community and industry that is coordinating the deployment of Immunoxpert in Europe. The two-year award was granted through the Horizon 2020 Fast Track to Innovation Pilot.
Thermo Fisher Scientific Inc., of Waltham, Mass., priced an offering of €1 billion aggregate principal amount of its 0.750 percent senior notes due 2024 and €600 million aggregate principal amount of its 1.375 percent senior notes due 2028 at the issue prices of 99.122 percent of the principal amount and 99.748 percent of the principal amount, respectively. The issuance of the notes is expected to close on or about Sept. 12. The notes will pay interest on an annual basis. Thermo Fisher said it intends to use the net proceeds of the offering to finance a portion of the estimated $4.2 billion price to acquire Fei Co., of Hillsboro, Ore., and to pay certain associated costs. The Fei acquisition is expected to close by Dec. 31.
Vivasure Medical plc, of Galway Ireland, completed a series C financing of €16.2million (US$18.3 million). Life Sciences Partners (LSP), of the Netherlands, led the round from its LSP Health Economics Fund, and Evonik Venture Capital, of Germany, co-led the financing alongside Panakès Partners, of Italy, with returning series A and B investors led by Fountain Healthcare Partners, of Ireland. Vivasure said the funding will support European commercialization of the company's Perqseal technology for percutaneous vessel closure, as well as an FDA regulatory study.